A possible antienuretic effect of reboxetine in children and adolescents with attention deficit/hyperactivity disorder: case series.
Reboxetine is a selective norepinephrine reuptake inhibitor.


OBJECTIVE
To evaluate the antienuretic effect of reboxetine in children with attention deficit and mood disorders.


METHODS
Six children aged 12-15 years with primary nocturnal enuresis and with attention deficit/hyperactivity disorder with or without other comorbid disorders were treated with reboxetine (4-8 mg/day). Monitoring of enuretic frequency was recorded at baseline and once a week for 6 weeks.


RESULTS
A statistically significant decrease in bedwetting was noted along the assessment points (p < 0.001), with the maximal change noted in the first week of treatment (p = 0.004). Reboxetine was well tolerated with minimal and transient side effects.


CONCLUSIONS
reboxetine may possess an antienuretic effect in some children with the attention deficit/hyperactivity disorder.
Toren
Paz
P
Tel Aviv-Brull Community Mental Health Center, 1 Geiger Street, Basement Floor, Ramat-Aviv, Tel Aviv 69341, Israel.
Ratner
Sharon
S
Laor
Nathaniel
N
Lerer-Amisar
Dana
D
Weizman
Abraham
A
D000293:Adolescent; D000704:Analysis of Variance; D001289:Attention Deficit Disorder with Hyperactivity / Q000150:complications / Q000188:drug therapy*; D002648:Child; D004775:Enuresis / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D006801:Humans; D008297:Male; D009025:Morpholines / Q000627:therapeutic use*; D000077593:Reboxetine; D013997:Time Factors; D016896:Treatment Outcome
D009025:Morpholines; D000077593:Reboxetine